Overview

Webcast ImageWebcast
Audentes Therapeutics Inc at Morgan Stanley 16th Annual Global Healthcare Conference (Replay)
09/12/18 at 8:10 a.m. ET
Audentes Therapeutics Inc at Morgan Stanley 16th Annual Global Healthcare Conference
Wednesday, September 12, 2018 8:10 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Audentes Therapeutics is a biotechnology company committed to the development and commercialization of innovative new gene therapy treatments for people with serious rare diseases. We are a focused, experienced and passionate team driven by the goal of improving the lives of patients.

We currently have four products in development, AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM), AT342 for the treatment of Crigler-Najjar Syndrome, AT307 for the treatment of CASQ2-related Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), and AT982 for the treatment of Pompe disease.
Stock Information
BOLD (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$40.05
Change (%) Stock is Up 1.06 (0.00%)
Volume224,551
Data as of 09/18/18 4:00 p.m. ET
Refresh quote
Stock chart for: BOLD.O.  Currently trading at $40.05 with a 52 week high of $46.18 and a 52 week low of $23.89.
Recent NewsMore >>
08/29/18
Audentes Therapeutics to Participate in Upcoming Investor Conferences
08/21/18
Audentes Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by the FDA to AT132 for the Treatment of X-Linked Myotubular Myopathy
08/09/18
Audentes Therapeutics to Present at the 2018 Wedbush PacGrow Healthcare Conference
Upcoming EventsMore >>
There are currently no events scheduled.
Primary IR Contact
Andrew H. Chang
Director, Investor Relations
Audentes Therapeutics, Inc.
E-mail: ir@audentestx.com

Data provided by Nasdaq. Minimum 15 minutes delayed.